CSCI Tingkat bathi reged Aeterna Zentaris

Simbol resmi perusahaan Aeterna Zentaris (CSCI)

COSCIENS Biopharma Inc. (CSCI) generates revenue through Macrilen licenses and the sale of diagnostic tests. The company's strategy relies on high-margin therapies for rare endocrine pathologies and growth hormone deficiency. The business is currently focusing on the organic development of its pipeline following the integration of new assets. The gross profit margin as a percentage of revenue illustrates production efficiency, while the 45.50 level reflects the status of the profitability parameter.

COSCIENS Biopharma Inc. (CSCI): Margin reged saka 10.08.2024 nganti 14.09.2025

Rincian analitis lan laporan data perusahaan COSCIENS Biopharma Inc (CSCI)

- nilai pasar lan prakiraan target analis:
Analisis dhasar perusahaan:CSCI - COSCIENS Biopharma
Barang utama COSCIENS Biopharma

For a fundamental valuation of COSCIENS Biopharma Inc. (CSCI), understanding the monetization efficiency of its intellectual property is critical. Gross margin measures the profit share after deducting direct production costs, reflecting the company's ability to convert revenue into operating capital. The annual gross margin trend demonstrates the scalability potential of the biopharmaceutical business, where proprietary molecules allow for the minimization of cost of goods sold amid global sales growth.